Pharmaceutical Technology
FEBRUARY 17, 2023
The agency proposes that pharma move away from the common maximum tolerated dose (MTD) to trial designs that prioritise drug dosage optimisation at different stages. In clinical trials, dose-ranging is testing different drug doses against each other to establish which works best.
Pharmaceutical Technology
AUGUST 5, 2022
Clinical trial design continues to increase in complexity, and temperature-controlled logistics – in particular cold chain and frozen and associated supply chains – must also advance to keep pace with technological developments. Temperature-controlled clinical trial supply chain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Phorum
JUNE 15, 2021
Antibody flunks post-exposure prevention study. The results of the STORM CHASER trial found there were 23 cases of COVID-19 among 273 people treated with a single dose of AZD7442 given as an intramuscular injection, compared to 17 out of 372 subjects in the placebo group.
XTalks
NOVEMBER 7, 2022
Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials.
XTalks
MAY 2, 2022
Lecanemab, the product of Phase IIb clinical research completed by BioArctic and collaborator Eisai, is one therapy making strides this year for Alzheimer’s disease. This year, the monoclonal antibody lecanemab is approaching final stages of investigation as a treatment for targeting the A?
Pharmaceutical Technology
AUGUST 24, 2022
The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1% FCM data are used to make clinical decisions around safety, efficacy, and pharmacodynamics.
BioPharma Reporter
DECEMBER 13, 2021
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Pharma Phorum
JANUARY 21, 2022
Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Overall, antibody levels were nearly 2.5 News R&D clinical trials coronavirus COVID-19 Omicron pharma vaccine
Riverside Clinical Research
SEPTEMBER 1, 2022
Velocity Clinical Research. The mission, at Velocity Clinical Research, is to help make the world a better place with a future filled with hope and extraordinary medical possibilities. Clinical study volunteers are also able to take a more active part in their own healthcare.
Pharma Phorum
NOVEMBER 6, 2022
The potential of monoclonal antibodies (mAbs) as therapies is indisputable. Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Natural Antibody.
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD).
XTalks
JULY 25, 2022
The BLA, which grants permission to distribute a biological therapy across states in the US, was accepted based on data from the company’s Phase III trial. Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs).
Bio Pharma Dive
JUNE 21, 2021
Final clinical trial results confirmed treatment dramatically reduced the risk of hospitalization and death among adults with mild-to-moderate COVID-19
Pharma Phorum
SEPTEMBER 4, 2020
Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. They said the trials would involve 440 adults at 11 sites across the US.
Bio Pharma Dive
JANUARY 20, 2021
Results from a clinical trial in nursing home residents and staff offered the first evidence Lilly's bamlanivimab could protect against, as well as treat, COVID-19
XTalks
APRIL 22, 2022
Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic.
Pharmaceutical Technology
JULY 21, 2022
AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment.
XTalks
OCTOBER 16, 2020
Inmazeb is a combination of three different antiviral monoclonal antibodies. However, that outbreak was controlled before Regeneron’s drug could be tested in a clinical trial. The PALM Trial.
BioTech 365
JUNE 9, 2022
Global Lung Cancer Antibodies Market, Drug Sales & Clinical Trials Insight Report to 2028 – ResearchAndMarkets.com Global Lung Cancer Antibodies Market, Drug Sales & Clinical Trials Insight Report to 2028 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Lung Cancer Antibodies Market, Drug … Continue reading → Business Wire
NY Times
APRIL 5, 2021
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic.
Scienmag
AUGUST 11, 2020
Infectious Emerging Diseases Clinical Trials Health Care Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Researchers/Scientists/Awards
BioTech 365
DECEMBER 10, 2020
Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027 Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027 Phase 1 Clinical Trials Demonstrate Safety of this Novel Monoclonal Antibody SINGAPORE–(BUSINESS WIRE)–In June … Continue reading → Business Wire
BioTech 365
DECEMBER 20, 2021
Global TROP2 Antibody Market & Clinical Trials Insight Research Report 2021-2026 – ResearchAndMarkets.com Global TROP2 Antibody Market & Clinical Trials Insight Research Report 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global TROP2 Antibody Market & Clinical Trials Insight 2026” report has been … Continue reading → Business Wire
NY Times
APRIL 5, 2021
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic.
BioTech 365
DECEMBER 29, 2021
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6026, a Monoclonal Antibody Targeting OX40 Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6026, a Monoclonal Antibody Targeting OX40 GUANGZHOU, China–(BUSINESS WIRE)–#ADCC–Bio-Thera Solutions, Ltd. (SH:
Scienmag
APRIL 21, 2021
Credit: NIAID A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19.
Scienmag
APRIL 13, 2021
Credit: NIAID A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun.
BioTech 365
DECEMBER 17, 2020
Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies ALACHUA, Fla.–(BUSINESS
BioTech 365
NOVEMBER 18, 2020
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: EU COVID-19 antibody ready for clinical trials. from European Biotechnology – first and foremost in European biotech [link].
XTalks
JANUARY 29, 2021
Data from Eli Lilly and Company’s (NYSE: LLY) Phase III clinical trial evaluating its monoclonal antibody drugs bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) show that combining the two significantly reduced the risk of COVID-19 hospitalizations and death by 70 percent.
XTalks
FEBRUARY 7, 2023
Rugo, MD, professor of Medicine and Director, Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, US and principal investigator of the TROPiCS-02 study, in the press release.
NY Times
NOVEMBER 5, 2021
Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Clinical Trials Antibodies Food and Drug Administration Merck & Company Inc Pfizer IncPfizer’s is the second pill to show effectiveness against Covid-19, and it is the first purpose-built to attack the virus that causes the disease.
XTalks
AUGUST 23, 2021
This is not a debate on approval,” said Stacie Weninger, PhD, president of the F-Prime Biomedical Research Initiative, in a focused topic session on the impact of drug approval on future clinical trials held on Tuesday July 27. Knopman, MD, a clinical neurologist at the Mayo Clinic.
Pharmaceutical Technology
MARCH 9, 2023
Global biopharmaceutical firm UCB and Cancer Research UK have entered a multi-project partnership to advance two of the former’s oncology antibody candidates through clinical trials.
NY Times
OCTOBER 19, 2021
Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Antibodies Immune System Johnson & Johnson Moderna Inc Pfizer Inc Food and Drug AdministrationThe F.D.A.
BioTech 365
DECEMBER 15, 2020
Global Trispecific Antibodies Market to 2024 – Opportunity & Clinical Trials Insights – ResearchAndMarkets.com Global Trispecific Antibodies Market to 2024 – Opportunity & Clinical Trials Insights – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024” … Continue reading → Business Wire
XTalks
MARCH 15, 2021
Eli Lilly (NASDAQ: LLY ) shared the latest results from a late-stage study which show its combination antibody COVID-19 treatment can reduce hospitalizations and deaths by an impressive 87 percent, compared with placebo. The antibody was developed in conjunction with Vancouver-based AbCellera.
XTalks
AUGUST 30, 2022
The CMA is for adult patients who do not have a history of factor VIII inhibitors and who do not have detectable antibodies to adeno-associated virus serotype 5 (AAV5). XTALKS WEBINAR: How Agile Clinical Trials Unlock Universal Access to Rare Disease Research.
XTalks
JANUARY 6, 2023
Last week, the FDA approved a new infusible medication from TG Therapeutics for adults with relapsing forms of multiple sclerosis (MS), which include clinically isolated syndrome (CIS), relapsing-remitting (RR) MS, and active secondary progressive MS (SPMS).
Pharma Phorum
MARCH 12, 2021
Sanofi and Translate BIO have begun a clinical trial of their potential mRNA COVID-19 shot, as the French pharma struggles to keep pace with rivals despite its background in vaccines. Clinical trial participants will receive one dose of MRT5500, or two doses 21 days apart.
Riverside Clinical Research
FEBRUARY 14, 2022
Pregnant women who have already developed CMV antibodies will most likely not transmit the virus to their unborn fetus, but pregnant mothers with new CMV cases may. Velocity Clinical Research conducts clinical research in an effort to safely protect people against infections.
Scienmag
AUGUST 10, 2020
– The COVID-19 Prevention Network (CoVPN) today announced two Phase 3 trials to determine whether monoclonal antibodies (mAbs) can prevent SARS-CoV-2, the virus that causes COVID-19. Biology Clinical Trials Infectious/Emerging Diseases Medicine/Health Public Health Virology
Expert insights. Personalized for you.
278 
Let's personalize your content